Evidence map›Paper›PMID 28877188›Full record

ArticlePloS one2017

Mitochondrial superclusters influence age of onset of Parkinson's disease in a gender specific manner in the Cypriot population: A case-control study.

Andrea Georgiou, Christiana A Demetriou, Alexandros Heraclides, Yiolanda P Christou, Eleni Leonidou, Panayiotis Loukaides, Elena Yiasoumi, Dimitris Panagiotou, Panayiotis Manoli, Pippa Thomson and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Mitochondrial DNA Repair in Neurodegenerative Diseases and Ageing.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Frontiers in neuroscience · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Andrea GeorgiouNeurology Clinic D, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Christiana A DemetriouNeurology Clinic D, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Alexandros HeraclidesDepartment of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.
Yiolanda P ChristouNeurology Clinic D, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Eleni LeonidouNeurology Clinic C, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Panayiotis LoukaidesLimassol General Hospital, Limassol, Cyprus.
Elena YiasoumiPrivate Neurology Clinic, Larnaca, Cyprus.
Dimitris PanagiotouDepartment of Biological Sciences, University of Cyprus, Nicosia, Cyprus.
Panayiotis ManoliDepartment of Cardiovascular Genetics and the Laboratory of Forensic Genetics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Pippa ThomsonCentre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Maria A LoizidouThe Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Andreas HadjisavvasThe Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Eleni Zamba-PapanicolaouNeurology Clinic D, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.ORCID http://orcid.org/0000-0001-7727-9714
Cyprus Institute of Neurology and Genetics · CYInstitute of Genetics and Cancer · GBLarnaca College · CYLimassol General Hospital · CYUniversity of Cyprus · CYUniversity of Nicosia · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite evidence supporting an involvement of mitochondrial dysfunction in the pathogenesis of some neurodegenerative disorders, there are inconsistent findings concerning mitochondrial haplogroups and their association to neurodegenerative disorders, including idiopathic Parkinson's disease (PD).

methodsTo test this hypothesis for the Greek-Cypriot population, a cohort of 230 PD patients and 457 healthy matched controls were recruited. Mitochondrial haplogroup distributions for cases and controls were determined. Association tests were carried out between mitochondrial haplogroups and PD.

resultsMitochondrial haplogroup U was associated with a reduced PD risk in the Cypriot population. After pooling mitochondrial haplogroups together into haplogroup clusters and superclusters, association tests demonstrated a significantly protective effect of mitochondrial haplogroup cluster N (xR) and supercluster LMN for PD risk only in females. In addition, for female PD cases belonging to UKJT and R (xH, xUKJT) haplogroup, the odds of having a later age of onset of PD were 13 and 15 times respectively higher than the odds for female cases with an H haplogroup.

conclusionStatistically significant associations regarding PD risk and PD age of onset were mostly detected for females thus suggesting that gender is a risk modifier between mitochondrial haplogroups and PD status / PD age of onset. The biological mechanisms behind this gender specificity remain to be determined.

Indexed as

Sex CharacteristicsAgedAge of OnsetCase-Control StudiesConfidence IntervalsDNA, MitochondrialFemaleGreeceHaplotypesHumansMaleMitochondriaOdds RatioOpen Reading FramesParkinson DiseasePolymorphism, Single NucleotideDNA, Mitochondrial

Identifiers

PMID28877188
PMCPMC5587277
OpenAlexW2752378527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.